Endurance Research Group, School of Sport & Exercise Sciences, University of Kent, Canterbury, UK.
Lincoln Institute for Health, University of Lincoln, Lincoln, UK.
Eur J Sport Sci. 2021 May;21(5):771-780. doi: 10.1080/17461391.2020.1771429. Epub 2020 Jun 30.
Upper respiratory tract infection (URTI) can compromise athlete preparation and performance, so countermeasures are desirable. The aim of this study was to assess the effects of ColdZyme® Mouth Spray (ColdZyme) on self-reported upper respiratory tract infection in competitive endurance athletes under free-living conditions. One hundred and twenty-three endurance-trained, competitive athletes (recruited across 4 sites in England, UK) were randomised to control (no treatment, = 61) or ColdZyme ( = 62) for a 3-month study period (between December 2017 and March 2018; or December 2018 and April 2019). They recorded daily training and illness symptoms (Jackson common cold questionnaire) during the study period. A total of 130 illness episodes were reported during the study with no difference in incidence between groups (episodes per person: 1.1 ± 0.9 Control, 1.0 ± 0.8 ColdZyme, = 0.290). Episode duration was significantly shorter in ColdZyme compared to Control: Control 10.4 ± 8.5 days vs. ColdZyme 7.7 ± 4.0 days, = 0.016). Further analysis to compare episodes with poor vs. good compliance with ColdZyme instructions for use (IFU) within the ColdZyme group showed a greater reduction in duration of URTI when compliance was good (9.3 ± 4.5 days in ColdZyme poor IFU compliance vs. 6.9 ± 3.5 days in ColdZyme good IFU compliance, = 0.040). ColdZyme may be an effective countermeasure to reduce URTI duration, which was significantly lower (by 26-34%) in the ColdZyme treatment group (with no influence on incidence). This may have implications for athlete performance.
上呼吸道感染（URTI）会影响运动员的准备和表现，因此需要采取对策。本研究旨在评估 ColdZyme®口腔喷雾（ColdZyme）在自由生活条件下对竞技耐力运动员上呼吸道感染自我报告的影响。123 名经过训练的竞技耐力运动员（在英国的 4 个地点招募）被随机分配到对照组（无治疗，n=61）或 ColdZyme 组（n=62），进行为期 3 个月的研究（2017 年 12 月至 2018 年 3 月；或 2018 年 12 月至 2019 年 4 月）。他们在研究期间每天记录训练和疾病症状（Jackson 普通感冒问卷）。在研究期间共报告了 130 次疾病发作，两组的发病率没有差异（每人发作次数：1.1±0.9 对照组，1.0±0.8 ColdZyme 组，=0.290）。与对照组相比，ColdZyme 组的发作持续时间明显缩短：对照组 10.4±8.5 天，ColdZyme 组 7.7±4.0 天，=0.016）。进一步分析比较 ColdZyme 组内按使用说明（IFU）使用 ColdZyme 与不按 IFU 使用 ColdZyme 的发作，发现按 IFU 使用 ColdZyme 时，URTI 的持续时间缩短更明显（按 IFU 使用 ColdZyme 效果差时 9.3±4.5 天，按 IFU 使用 ColdZyme 效果好时 6.9±3.5 天，=0.040）。ColdZyme 可能是一种有效的减少 URTI 持续时间的对策，在 ColdZyme 治疗组（对发病率无影响），URTI 持续时间明显缩短（降低 26-34%）。这可能对运动员的表现有影响。
